Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,301–2,400 of 15,747
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 52
Kar, S., Devnath, P., Emran, T. B., Tallei, T. E., Mitra, S., & Dhama, K. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.604 · Cited by 50
Sex-disaggregated data in COVID-19 vaccine trials
Vijayasingham, L., Bischof, E. Y., & Wolfe, J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00384-6 · Cited by 51
Higashi‐Kuwata, N., Tsuji, K., Hayashi, H., Bulut, H., Kiso, M., Imai, M., Ogata-Aoki, H., Ishii, T. M., Kobayakawa, T., Nakano, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36729-0 · Cited by 55
Anderson, M., Stec, M., Rewane, A., Landay, A., Cloherty, G., & Moy, J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.19741 · Cited by 47
Microfluidic synthesis of nanomaterials for biomedical applications
Huang, Y., Liu, C., Feng, Q., & Sun, J. (2023) · Nanoscale Horizons · doi:10.1039/d3nh00217a · Cited by 53
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here
Halperin, D. T., Hearst, N., Hodgins, S., Bailey, R. C., Klausner, J. D., Jackson, H., Wamai, R. G., Ladapo, J. A., Over, M., Baral, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12082-z · Cited by 61
Self-citationPatients with history of covid-19 had more side effects after the first dose of covid-19 vaccine
Tissot, N., Brunel, A., Bozon, F., Rosolen, B. B., Chirouze, C., & Bouiller, K. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.047 · Cited by 46
“In immunogenicity trials [2,4,5], the frequency and severity of reactogenicity symptoms were higher after the second dose of vaccine than the first one except for vomiting and diarrhoea, which were generally similar regardless of dose.”
BackgroundAcquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine
Maayaan, H., Kirgner, I., Gutwein, O., Tzarfati, K. H., Rahimi‐Levene, N., Koren‐Michowitz, M., & Blickstein, D. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15420 · Cited by 46
Social Bonding and Public Trust/Distrust in COVID-19 Vaccines
Ramkissoon, H. R. (2021) · Sustainability · doi:10.3390/su131810248 · Cited by 54
“[6] argue that safe and effective COVID-19 vaccines are urgently needed to help address the pandemic.”
BackgroundResearch Status and Prospect of Non-Viral Vectors Based on siRNA: A Review
Tong, L., Liu, D., Cao, Z., Zheng, N., Mao, C., Liu, S., He, L., & Liu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043375 · Cited by 54
del Fresno, C., García‐Arriaza, J., Martínez-Cano, S., Heras‐Murillo, I., Jarit-Cabanillas, A., Amores-Iniesta, J., Brandi, P., Dunphy, G., Suay‐Corredera, C., Pricolo, M. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748103 · Cited by 51
“Vaccines based on messenger RNA (1, 2) or viral vectors (3, 4) expressing the SARS-CoV-2 spike (S) protein showed efficacies between 60 and 95%.”
BackgroundLv, K., Yu, Z., Wang, J., Li, N., Wang, A., Xue, T., Wang, Q., Shi, Y., Han, L., Qin, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202404684 · Cited by 64
Valcarce, V., Stafford, L. S., Neu, J., Cacho, N. T., Parker, L. A., Mueller, M., Burchfield, D. J., Li, N., & Larkin, J. (2021) · Breastfeeding Medicine · doi:10.1089/bfm.2021.0122 · Cited by 50
“9 Race White Asian Ethnicity Non- Hispanic Hispanic 20 (95) 1 (5) 18 (85) 3 (15) Profession Healthcare worker Body mass index (kg/m2)b* Normal/Healthy weight Overweight Obese History of allergies* History of asthma* History of inadequate immune response to vaccine* Family history of Cancer* Family history of autoimmun…”
Shrotri, M., Fragaszy, E., Geismar, C., Nguyen, V., Beale, S., Braithwaite, I., Byrne, T., Fong, W. L. E., Kovar, J., Navaratnam, A. M. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33550-z · Cited by 84
Butsch, W. S., Hajduk, A. M., Cardel, M. I., Donahoo, W. T., Kyle, T. K., Stanford, F. C., Zeltser, L. M., Kotz, C. M., & Jastreboff, A. M. (2021) · Obesity · doi:10.1002/oby.23251 · Cited by 49
Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals
Nittner‐Marszalska, M., Rosiek‐Biegus, M., Kopeć, A., Pawłowicz, R., Kosińska, M., Łata, A., & Szenborn, L. (2021) · Vaccines · doi:10.3390/vaccines9060553 · Cited by 49
“Comirnaty was approved for use in the USA, Canada, and Europe in December 2020 [13,14].”
MethodHod, T., Ben‐David, A., Olmer, L., Levy, I., Ghinea, R., Mor, E., Lustig, Y., & Rahav, G. (2021) · Transplantation · doi:10.1097/tp.0000000000003889 · Cited by 44
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 102
“Another breakthrough for LNP-encapsulated mRNA vaccines was during the global pandemic of SARS-CoV2, when Moderna and BioNTech/Pfizer resorted to lipid nanoparticles as carrier to successfully deliver mRNA against the COVID-19 virus (Polack et al., 2020a; Sahly et al., 2021).”
BackgroundTorreggiani, M., Blanchi, S., Fois, A., Fessi, H., & Piccoli, G. B. (2021) · Kidney International · doi:10.1016/j.kint.2021.04.010 · Cited by 52
“To the editor: On December 21, 2020, the European Commission granted conditional marketing approval to the BNT162b2 coronavirus disease 2019 (COVID-19) mRNA vaccine developed by BioNTech.(1,2) In the general population, the first dose ofBNT162b2was reported to produce a rapid antibody response with 52% efficacy in pre…”
BackgroundOlfactory immunology: the missing piece in airway and CNS defence
Wellford, S. A., & Moseman, E. A. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00972-9 · Cited by 57
Mostert, S., Hoogland, M., Huibers, M. H. W., & Kaspers, G. J. L. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000282 · Cited by 63
“32 33 36 On 9 April 2021, the overall COVID-19 Infection Fatality Rate was reduced to 0.15% and expected to further decline with the widespread use of vaccinations, prior infections and the evolution of new and milder variants.”
BackgroundInfluentialRetractedCOVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations
Duly, K., Farraye, F. A., & Bhat, S. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab344 · Cited by 52
“3% of the study population (121 patients in total) but were not included in the primary efficacy and safety analysis.(12) The Moderna vaccine study included a slightly larger number of patients with stable HIV infection (159, or 0.”
BackgroundmRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer
Malla, R. R., Srilatha, M., Farran, B., & Nagaraju, G. P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.024 · Cited by 55
Qassim, S. H., Chemaitelly, H. S., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac068 · Cited by 50
Zeng, Y., Sentí, M. E., Labonia, M. C. I., Papadopoulou, P., Brans, M. A. D., Dokter, I., Fens, M. H. A. M., van Mil, A., Sluijter, J. P. G., Schiffelers, R. M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c05341 · Cited by 49
Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate
Nkanga, C. I., Ortega-Rivera, O. A., Shin, M. D., Moreno‐Gonzalez, M. A., & Steinmetz, N. F. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00112 · Cited by 47
Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., Lewnard, J. A., California COVID-19 Case-Control Study Team, Samani, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab640 · Cited by 46
Abraham, N., Spruin, S., Rossi, T. M., FIREMAN, B. H., Zafack, J. G., Blaser, C., Shaw, A. K., Hutchings, K., & Ogunnaike-Cooke, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.048 · Cited by 45
“By March 2021, post-market safety surveillance systems in Israel, the United States and other countries detected a disproportionate number of reports of myocarditis and/or pericarditis (inflammation of the heart muscle and/or lining of the heart muscle) that had not been picked up during clinical trials [3,4], occurri…”
Rolfo, C., Meshulami, N., Russo, A., Krammer, F., García‐Sastre, A., Mack, P. C., Gomez, J. E., Bhardwaj, N., Benyounes, A., Sirera, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.001 · Cited by 53
Intapiboon, P., Seepathomnarong, P., Ongarj, J., Surasombatpattana, S., Uppanisakorn, S., Mahasirimongkol, S., Sawaengdee, W., Phumiamorn, S., Sapsutthipas, S., Sangsupawanich, P., et al. (2021) · Vaccines · doi:10.3390/vaccines9121375 · Cited by 51
“The mRNA-1273 vaccine contain higher doses (100 μg) compared to the BNT162b2 mRNA vaccine (30 μg), or the mRNA-1273, which is just simply more immunogenic compared to another mRNA vaccine [32,33].”
BackgroundHwang, Y., Shepherd, S. J., Kim, D., Mukalel, A. J., Mitchell, M. J., Issadore, D., & Lee, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c12965 · Cited by 58
The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials
Ali, J. K., & Riches, J. C. (2021) · Cancers · doi:10.3390/cancers13235924 · Cited by 53
“However, effective vaccines for COVID-19 were developed, tested, and licensed with a year of the virus first being discovered [53-55].”
BackgroundSARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Iketani, S., & Ho, D. D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.008 · Cited by 51
Tung, T., Lin, X., Chen, Y., Zhang, M., & Zhu, J. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2016401 · Cited by 48
“Safety over a median of 2 months was similar to that of other viral vaccines [7,21,22].”
ResultDuan, X., Zhang, Y., Guo, M., Fan, N., Chen, K., Qin, S., Xiao, W., Zheng, Q., Huang, H., Wei, X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.015 · Cited by 46
mRNA Vaccines: Why Is the Biology of Retroposition Ignored?
Domazet‐Lošo, T. (2022) · Genes · doi:10.3390/genes13050719 · Cited by 50
The Use of COVID-19 Vaccines in Patients with SLE
Tang, W., Gartshteyn, Y., Ricker, E., Inzerillo, S., Murray, S., Khalili, L., & Askanase, A. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01046-2 · Cited by 49
Terpos, E., Gavriatopoulou, M., Fotiou, D., Giatra, C., Asimakopoulos, I., Dimou, M., Sklirou, A. D., Ntanasis‐Stathopoulos, I., Darmani, I., Briasoulis, Α., et al. (2021) · Cancers · doi:10.3390/cancers13174480 · Cited by 45
“The efficacy of the BNT162b2 mRNA vaccine against SARS-CoV-2 in healthy adults has been clearly demonstrated [29].”
BackgroundHuang, X., Yu, M., Fu, G., Lan, G., Li, L., Yang, J., Qiao, Y., Zhao, J., Qian, H., Zhang, X., et al. (2021) · JMIR Public Health and Surveillance · doi:10.2196/31125 · Cited by 47
(2021) · doi:10.1101/2021.09.02.21262979 · Cited by 46
“The incidence of reverse transcription-polymerase chain reaction (RT-PCR) confirmed cases of COVID-19 has increased substantially in England since the Delta variant became established during April to May 2021 [6].”
BackgroundInfluentialWang, J., Wu, Q., Wang, X., Liu, H., Chen, M., Xu, L. N., Zhang, Z., Li, K., Li, W., & Zhong, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01229-z · Cited by 55
“Notably, the effective delivery of mRNA via nanoparticle-mediated strategies has revolutionized vaccine development, with mRNA vaccines being successfully employed to combat coronavirus disease 2019 (COVID-19) [113, 114].”
MethodBigay, J., Grand, R. L., Martinon, F., & Maisonnasse, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932408 · Cited by 57
“demonstrated that immunization of SARS survivors with the BNT162b2 mRNA vaccine (Pfizer – BioNTech vaccine (Polack et al., 2020)) induced a broad spectrum of pansarbecovirus neutralizing antibodies in humans (Tan et al.”
BackgroundA regulatory role of circRNA-miRNA-mRNA network in osteoblast differentiation
Mohanapriya, R., Akshaya, R. L., & Selvamurugan, N. (2021) · Biochimie · doi:10.1016/j.biochi.2021.11.001 · Cited by 47
The politics of vaccine hesitancy in the United States
Cao, J., Ramirez, C. M., & Alvarez, R. M. (2021) · Social Science Quarterly · doi:10.1111/ssqu.13106 · Cited by 50
Broad-spectrum pan-genus and pan-family virus vaccines
Tan, C. W., Valkenburg, S., Poon, L. L. M., & Wang, L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.017 · Cited by 44
Odeh‐Natour, R., Shapira, M., Estrada, D., Freimann, S., Tal, Y., Atzmon, Y., Bilgory, A., Aslih, N., Raya, Y. S. A., & Shalom‐Paz, E. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13530 · Cited by 49
Mark, C., Gupta, S., Punnett, A., Upton, J. E. M., Orkin, J., Atkinson, A. R., Clarke, L., Heisey, A., McGovern, C., & Alexander, S. W. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29295 · Cited by 43
Reischig, T., Kacer, M., Vlas, T., Drenko, P., Kielberger, L., Machova, J., Topolčan, O., Kučera, R., & Kormunda, S. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16902 · Cited by 53
Sakuraba, A., Luna, A., & Micić, D. (2022) · Viruses · doi:10.3390/v14081822 · Cited by 47
“Due to the lack of efficacious therapies for COVID-19, vaccinations that could prevent infections are of importance in lowering the mortality risk [11].”
BackgroundWang, L., Davis, P. B., Kaelber, D. C., & Xu, R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12669 · Cited by 46
“[14].”
InfluentialRisk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
Smits, P. D., Gratzl, S., Simonov, M., Nachimuthu, S., Cartwright, B. M. G., Wang, M. D., Baker, C., Rodriguez, P., Bogiages, M., Althouse, B. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.038 · Cited by 49
“The successful development of multiple COVID-19 vaccines has led to a global vaccination effort with the goal of reducing severe COVID-19 infection and mortality [1,2].”
BackgroundSharma, M., Batra, K., & Batra, R. (2021) · Healthcare · doi:10.3390/healthcare9101273 · Cited by 53
Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
Yap, C., Ali, A., Prabhakar, A., Prabhakar, A., Pal, A., Lim, Y. Y., & Kakodkar, P. (2021) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355211059791 · Cited by 54
COVID-induced thyroid autoimmunity
Brancatella, A., Viola, N., Santini, F., & Latrofa, F. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101742 · Cited by 55
Dębska-Ślizień, A. M., Ślizień, Z., Muchlado, M., Kubanek, A., Piotrowska, M., Dąbrowska, M., Tarasewicz, A., Chamienia, A. L., Biedunkiewicz, B., Renke, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9101165 · Cited by 49
“To what extent cellular immunity, in the absence of detectable antibodies, is able to prevent severe infection in SOTR is yet to be determined [22].”
BackgroundInfluentialSpike protein of SARS-CoV-2 variants: a brief review and practical implications
Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., Silva, J. L. D. C., Maller, A., & Simão, R. D. C. G. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00743-z · Cited by 50
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria
Gerber, G. F., Yuan, X., Yu, J. M., et al. (2021) · Blood · doi:10.1182/blood.2021011548 · Cited by 46
Berec, L., Šmíd, M., Přibylová, L., Májek, O., Pavlík, T., Jarkovský, J., Zajíček, M., Weiner, J., Barusová, T., & Trnka, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270801 · Cited by 47
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
Li, H., Hu, Y., Li, J., He, J., Yu, G., Wang, J., & Lin, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02191-1 · Cited by 59
Barazzone, G. C., Teixeira, A. F., Azevedo, B. O. P., Damiano, D. K., Oliveira, M. P., Nascimento, A. L. T. O., & Lopes, A. P. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760291 · Cited by 59
Stewart-Jones, G., Elbashir, S. M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4100 · Cited by 56
Crespo, M., Barrilado-Jackson, A., Padilla, E., Eguía, J., Echeverría-Esnal, D., Cao, H., Faura, A., Folgueiras, M., Solà-Porta, E., Pascual-Guàrdia, S., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16854 · Cited by 52
COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
Hagens, A., İnkaya, A. Ç., Yıldırak, K., Sancar, M., van der Schans, J., Sancar, A. A., Ünal, S., Postma, M. J., & Yeğenoğlu, S. (2021) · Vaccines · doi:10.3390/vaccines9040399 · Cited by 51
Self-citationJung, S., Jeon, J. J., Kim, Y. H., Choe, S. J., & Lee, S. (2024) · Nature Communications · doi:10.1038/s41467-024-50656-8 · Cited by 59
Mahroum, N., Lavine, N., Ohayon, A., Seida, R., Alwani, A., Alrais, M., Zoubi, M., & Bragazzi, N. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872683 · Cited by 56
Koh, S. W. C., Tan, H. M., Lee, W. H., Mathews, J., & Young, D. (2022) · Vaccines · doi:10.3390/vaccines10030464 · Cited by 47
“Vaccination is a key public health strategy because it has been shown to be effective in reducing the risk of infection and severe disease [2,3].”
BackgroundShaw, C. A., August, A., Bart, S., Jackson-Booth, P.-G., Knightly, C., Brasel, T., Weaver, S. C., Zhou, H., & Panther, L. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.064 · Cited by 51
Ma, Z., Wong, S. W., Forgham, H., Esser, L., Lai, M., Leiske, M. N., Kempe, K., Sharbeen, G., Youkhana, J., Mansfeld, F. M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121539 · Cited by 48
Novel formulations and drug delivery systems to administer biological solids
Zhang, Y., Davis, D. A., AboulFotouh, K., Wang, J., Williams, D., Bhambhani, A., Zakrewsky, M., Maniruzzaman, M., Cui, Z., & Williams, R. O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.011 · Cited by 52
Testing Fractional doses of COVID-19 Vaccines
Więcek, W., Ahuja, A., Chaudhuri, E., Kremer, M. R., Gomes, A. S., Snyder, C. M., Tabarrok, A. T., & Tan, B. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116932119 · Cited by 46
“We are aware of an observational study of efficacy of primary vaccination with half-doses of ChAdOx1 nCoV-19 in Brazil (37) 6 and two randomized trials of immunogenicity comparing low doses with full doses for BNT162b2 (39) and mRNA-1273 (35).”
Tabarsi, P., Anjidani, N., Shahpari, R., Mardani, M., Sabzvari, A., Yazdani, B., Kafi, H., Fallah, N., Ebrahimi, A., Taheri, A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.09.001 · Cited by 53
Corneal graft rejection following COVID-19 vaccine
Rallis, K. I., Ting, D. S. J., Said, D. G., & Dua, H. S. (2021) · Eye · doi:10.1038/s41433-021-01671-2 · Cited by 50
Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.10780 · Cited by 54
Therapeutic strategies to fight COVID‐19: Which is the status artis?
Scavone, C., Mascolo, A., Rafaniello, C., Sportiello, L., Trama, U., Zoccoli, A., Bernardi, F. F., Racagni, G., Berrino, L., Castaldo, G., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15452 · Cited by 48
COVID-19 vaccine-associated subacute thyroiditis: an unusual suspect for de Quervain’s thyroiditis
Jeeyavudeen, M. S., Patrick, A. W., Gibb, F. W., et al. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-246425 · Cited by 46
Parino, F., Zino, L., Calafiore, G. C., & Rizzo, A. (2021) · International Journal of Robust and Nonlinear Control · doi:10.1002/rnc.5728 · Cited by 54
“we identify the four parameters governing the dynamics of the infection rate in (2), that is, the rate in the absence of severe NPIs β0, the activity reduction in the presence of severe NPIs bounds φNPI, the critical number of hospitalizations H, and the population reactivity to changes in the NPIs κ.”
BackgroundMethodSocial and structural determinants of COVID-19 vaccine uptake among racial and ethnic groups
Peña, J. M., Schwartz, M., Hernandez‐Vallant, A., & Sánchez, G. R. (2023) · Journal of Behavioral Medicine · doi:10.1007/s10865-023-00393-y · Cited by 54
Andretto, V., Dusi, S., Zilio, S., Repellin, M., Kryza, D., Ugel, S., & Lollo, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115080 · Cited by 52
Duong, T. V., Lin, C.-Y., Chen, S., Huang, Y., Okan, O., Dadaczynski, K., & Lai, C.-F. (2021) · Vaccines · doi:10.3390/vaccines9090985 · Cited by 90
Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Raju, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01743-x · Cited by 54
Bakos, T., Mészáros, T., Kozma, G. T., Berényi, P., Facskó, R., Farkas, H., Dézsi, L., Heirman, C., Koker, S. D., Schiffelers, R. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073595 · Cited by 54
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Nanishi, E., Levy, O., & Ozonoff, A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2045857 · Cited by 47
“Authorized/licensed COVID-19 mRNA vaccines had shown remarkable efficacy and real-world effectiveness against both asymptomatic and symptomatic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including in adults aged 65 or older.(1,2) However, accumulating evidence suggests that vaccine…”
BackgroundDorigatti, I., Lavezzo, E., Manuto, L., Ciavarella, C., Pacenti, M., Boldrin, C., Cattai, M., Saluzzo, F., Franchin, E., Vecchio, C. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24622-7 · Cited by 48
Razonable, R. R., Aloia, N. C. E., Anderson, R. J., Anil, G., Arndt, L. L., Arndt, R. F., Ausman, S. E., Bell, S. J., Bierle, D. M., Billings, M. L., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.03.010 · Cited by 44
Early human B cell signatures of the primary antibody response to mRNA vaccination
Kardava, L., Rachmaninoff, N., Lau, W. W., Buckner, C. M., Trihemasava, K., de Assis, F. L., Wang, W., Zhang, X., Wang, Y., Chiang, C.-I., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204607119 · Cited by 45
Novak, N., Tordesillas, L., & Cabanillas, B. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1939696 · Cited by 50
Scherlinger, M., Pijnenburg, L., Chatelus, E., Arnaud, L., Gottenberg, J.-E., Sibilia, J., & Felten, R. (2021) · Vaccines · doi:10.3390/vaccines10010046 · Cited by 45
“Fev r/chills and gastro-intestinal symptoms were the most frequently reported worsened symptoms, but are al o commonly reported after SARS-CoV-2 vaccination in he general population [10].”
BackgroundComparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
Kang, Y. M., Minn, D., Lim, J., Lee, K.-D., Jo, D. H., Choe, K. W., Kim, M. J., Kim, J. M., & Kim, K. N. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e311 · Cited by 50
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Hoteit, R., & Yassine, H. M. (2022) · Vaccines · doi:10.3390/vaccines10060919 · Cited by 51
“Based on data gathered between 27 July 2020 and 14 November 2020, Polack et al. (2020) found that a two-dose regimen of BNT162b2 (30 µg per dose administered 21 days apart) provided 95% (95% CI: 90.3 to 97.6) protection against the COVID-19 Delta variant in people aged 16 years and older [271].”
BackgroundMethodInfluentialThe Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 48
Caring for older adults during the COVID-19 pandemic
Prendki, V., Tiseo, G., & Falcone, M. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.040 · Cited by 27
“BNT162b2 (mRNA) [58,61] Phase I clinical study”
Roberts, C. H., Brindle, H. E., Rogers, N. T., Eggo, R. M., Enria, L., & Lees, S. S. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.745630 · Cited by 53
Wong, C. K. H., Lau, K. T. K., Xiong, X., Au, I. C. H., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Li, X., Chan, E. W., Gao, L., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004018 · Cited by 47
“While vaccine reactogenicity was transient, with mainly mild to moderate adverse effects, serious adverse events such as lymphadenopathy, arrhythmia, and leg paresthesia were recorded among BNT162b2 recipients in the clinical trial [13].”
BackgroundMucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
Fröberg, J., & Diavatopoulos, D. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000724 · Cited by 49
Ontañón, J., Blas, J., de Cabo, C., Santos, C. P., Taravilla, E. R.-E., García, A., Marín, L., Sáez, L., Beato, J. L., Rada, R., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103656 · Cited by 45
Cardiovascular consequences of viral infections: from COVID to other viral diseases
Schultheiß, H., Baumeier, C., Pietsch, H., Bock, C. –., Poller, W. C., & Escher, F. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab315 · Cited by 54
Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
Hong, J., Kwon, H. J., Cachau, R., Chen, C. Z., Butay, K. J., Duan, Z., Li, D., Ren, H., Liang, T., Zhu, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201433119 · Cited by 49
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.